DK2320923T3 - Trunkerede analoger af glucoseafhængigt insulinotropt polypeptid - Google Patents

Trunkerede analoger af glucoseafhængigt insulinotropt polypeptid Download PDF

Info

Publication number
DK2320923T3
DK2320923T3 DK09805288T DK09805288T DK2320923T3 DK 2320923 T3 DK2320923 T3 DK 2320923T3 DK 09805288 T DK09805288 T DK 09805288T DK 09805288 T DK09805288 T DK 09805288T DK 2320923 T3 DK2320923 T3 DK 2320923T3
Authority
DK
Denmark
Prior art keywords
cys
hgip
psu
seq
deleted
Prior art date
Application number
DK09805288T
Other languages
English (en)
Inventor
Zheng Xin Dong
Yeelana Shen
Daniel B Deoliveira
Original Assignee
Ipsen Pharma Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Pharma Sas filed Critical Ipsen Pharma Sas
Application granted granted Critical
Publication of DK2320923T3 publication Critical patent/DK2320923T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Child & Adolescent Psychology (AREA)

Claims (14)

1. Forbindelse med formel (I), (R2R3)-A1-A2-A3-A4-A5-A6-A7-AS-A,-A!0-A11-A12-A13-A14-A15-A16-A17-A18-A19-A20-A2I-A22-A23-A24-A25-A2É-A27-A28-A2>-A30-A31-A32-A33-A34-A3S-A:w-A37-Aæ-A35-A4O-A41-A42-A43-R1, (I) hvor: A1 er deleteret; A2 er Ala, 4Hppa eller deleteret; A3 er Glu, 4Hyp, Pro eller deleteret; A4 er Gly eller deleteret; A5 er Thr eller deleteret; A6 er Phe eller deleteret; A7er A5c eller A6c; A8 er Ser eller Chc-Ser; A9 er Asp; A10er Tyr; A11 er Ser, A6c eller Aib; A12er Ile; A13er Ala eller Aib; A14er Met, A6c eller Nle; A15er Asp; A16er Lys; A17er Ile; A18er His; A19er Gin; A20er Gin; A21 er Asp; A22er Phe; A23er Val; A24 er Asn; A21 er Trp; A26 er Leu; A27er Leu; A28 er Ala; A29er Gin; A30 er Lys; A31 er Gly, Cys(Hsu), Cys(Psu), 2Nal, D-2Nal, 0rn(N-C(0)-(CH2)4-CH3), 0m(N-C(0)-(CH2)8-CH3), 0rn(N-C(0)-(CH2)i2-CH3) eller deleteret; A32er Lys, Cys(Psu) eller deleteret; A33er Lys, Cys(Psu) eller deleteret; A34 er Asn, Cys(Psu), 0m(N-C(0)-(CH2)8-CH3) eller deleteret; A35er Asp, Cys(Psu) eller deleteret; A36er Trp, Cys(Psu) eller deleteret; A37er Lys, Cys(Psu) eller deleteret; A38er His, Cys(Psu) eller deleteret; A39er Asn, Cys(Psu) eller deleteret; A40er Ile, Cys(Psu) eller deleteret; A41 er Thr eller deleteret; A42 er Gin eller deleteret; A43 er Gin eller deleteret; R1 er OH eller NH2; hver af R2 og R3 er udvalgt uafhængigt fra gruppen bestående af H eller (Cr C30)acyl; forudsat, at når R2er (CrC30)acyl, så er R3 H; og forudsat, at når A2 er 4Hppa, så er R2 og R3 deleteret; og forudsat, at mindst én af A2, A3, A4, A5, A6, A8, A9, A11, A13, A14, A31, A32, A33, A34, A35, A36, A37, A38, A39 og A40 ikke er aminosyreresten af den tilsvarende position af naturligt GIP; eller et farmaceutisk acceptabelt salt deraf.
2. Forbindelse ifølge krav 1, hvor forbindelsen er: (Ac-A6c7, Gln43)hGIP(7-43)-OH (SEQ ID NR: 29); (Ac-A6c7)hGIP(7-42)-OH (SEQ ID NR: 4); [Ac-A6c7, Cys(Psu)40]hGIP(7-42)-OH (SEQ ID NR: 5); [Ac-A6c7, Cys(Psu)39]hGIP(7-42)-OH (SEQ ID NR: 6); [Ac-A6c7, Cys(Psu)38]hGIP(7-42)-OH (SEQ ID NR: 7); [Ac-A6c7, Cys(Psu)36]hGIP(7-42)-OH (SEQ ID NR: 8); [Ac-A6c7, Cys(Psu)35]hGIP(7-42)-OH (SEQ ID NR: 9); [Ac-A6c7, Cys(Psu)34]hGIP(7-42)-OH (SEQ ID NR: 10); [Ac-A6c7, Cys(Psu)33]hGIP(7-42)-OH (SEQ ID NR: 11); [Ac-A6c7, Cys(Psu)32]hGIP(7-42)-OH (SEQ ID NR: 12); [Ac-A6c7, Cys(Psu)31]hGIP(7-42)-OH (SEQ ID NR: 13); [Ac-A6c7, Cys(Psu)37]hGIP(7-42)-OH (SEQ ID NR: 14); [Ac-A6c7, 0rn31(N-C(0)-(CH2)i2-CH3)]hGIP(7-42)-0H (SEQ ID NR: 15); [Ac-A6c7, 0rn31(N-C(0)-(CH2)8-CH3)]hGIP(7-42)-0H (SEQ ID NR: 16); [A6c7, 0rn31(N-C(0)-(CH2)8-CH3)]hGIP(7-42)-0H (SEQ ID NR: 17); [CH3-(CH2)8-C(0)-A6c7, 0rn31(N-C(0)-(CH2)8-CH3)]hGIP(7-42)-0H (SEQ ID NR: 18); [Ac-A6c7, 0rn31(N-C(0)-(CH2)4-CH3)]hGIP(7-42)-0H (SEQ ID NR: 19); [A6c7, 0rn31(N-C(0)-(CH2)4-CH3)]hGIP(7-42)-0H (SEQ ID NR: 20); [CH3-(CH2)4-C(0)-A6c7, 0rn31(N-C(0)-(CH2)4-CH3)]hGIP(7-42)-0H (SEQ ID NR: 21); [Ac-A6c7, 0rn34(N-C(0)-(CH2)8-CH3)]hGIP(7-42)-0H (SEQ ID NR: 22); [A6c7, 0rn34(N-C(0)-(CH2)8-CH3)]hGIP(7-42)-0H (SEQ ID NR: 23); [CH3-(CH2)8-C(0)-A6c7, 0rn34(N-C(0)-(CH2)8-CH3)]hGIP(7-42)-0H (SEQ ID NR: 24); [Ac-A6c7, Cys(Hsu)31]hGIP(7-42)-OH (SEQ ID NR: 25); [A6c7, Cys(Hsu)31]hGIP(7-42)-OH (SEQ ID NR: 26); (Ac-A6c7, 2Nal31)hGIP(7-42)-OH (SEQ ID NR: 27); (Ac-A6c7, D-2Nal31) hGIP(7-42)-OH; (Ac-4Hyp3, A6c7)hGIP(3-42)-OH (SEQ ID NR: 28); [Ac-A6c7, Cys(Psu)31]hGIP(7-34)-NH2 (SEQ ID NR: 30); [Ac-A6c7, Cys(Psu)31]hGIP(7-31)-NH2( SEQ ID NR: 31); [Ac-Phe6, A6c7, Cys(Psu)31]hGIP(6-42)-OH (SEQ ID NR: 32); [A6c7, Cys(Psu)31]hGIP(6-42)-OH (SEQ ID NR: 33); (Ac-Phe6, A6c7) hGIP(6-30)-NH2(SEQ ID NR: 34); [Ac-Phe6, A6c7, Cys(Psu)31]hGIP(6-31 )-NH2 (SEQ ID NR: 35); [A6c7, Cys(Psu)31]hGIP(6-31 )-NH2 (SEQ ID NR: 36); (A5c7, Nle14)hGIP(6-30)-NH2 (SEQ ID NR: 37); (A6c7, Nle14)hGIP(6-30)-NH2 (SEQ ID NR: 38); eNer (4Hppa2, 4Hyp3, A6c7)hGIP(2-42)-OH (SEQ ID NR: 44); eller et farmaceutisk acceptabelt salt deraf.
3. Forbindelse ifølge krav 1, hvor: A2 er deleteret; A3 er deleteret; A4 er deleteret; A5 er deleteret; A6er deleteret; A7er A5c eller A6c; A8er Ser; A9er Asp; A10er Tyr; A11 er Ser; A12er lie; A13er Ala; A14er Met; A31 er Gly, Cys(Hsu), Cys(Psu), 2Nal, D-2Nal, 0rn(N-C(0)-(CH2)4-CH3), 0rn(N-C(0)-(CH2)8-CH3) eller 0rn(N-C(0)-(CH2)i2-CH3); A32 er Lys eller Cys(Psu); A33 er Lys eller Cys(Psu); A34 er Asn, Cys(Psu) eller 0rn(N-C(0)-(CH2)8-CH3); A35 er Asp eller Cys(Psu); A36 er Trp eller Cys(Psu); A37 er Lys eller Cys(Psu); A38 er His eller Cys(Psu); A39 er Asn eller Cys(Psu); A40er Ile eller Cys(Psu); A41 er Thr; A42er Gin; og A43 er deleteret; eller et farmaceutisk salt deraf.
4. Forbindelse ifølge krav 1, hvor: A43 er deleteret; A2 er 4Hppa; og mindst én af A3, A11, A13 og A14 ikke er aminosyreresten af den tilsvarende position af naturligt GIP; eller et farmaceutisk salt deraf.
5. Forbindelse ifølge krav 1, hvor: A2 til A5og A31 til A43 er deleteret; og mindst én af A6, A11 og A14 ikke er aminosyreresten af den tilsvarende position af naturligt GIP; eller et farmaceutisk salt deraf.
6. Forbindelse ifølge krav 1, hvor: A2 til A6 og A43 er deleteret; og mindst én af Asog A31 ikke er aminosyreresten af den tilsvarende position af naturligt GIP; eller et farmaceutisk salt deraf.
7. Forbindelse ifølge krav 1, hvor: A2 til A5 og A43 er deleteret; og mindst én af A6og A31 ikke er aminosyreresten af den tilsvarende position af naturligt GIP; eller et farmaceutisk salt deraf.
8. Forbindelse ifølge krav 1, hvor: A2 til A5og A32 til A43er deleteret; og mindst én af A6 og A31 ikke er aminosyreresten af den tilsvarende position af naturligt GIP; eller et farmaceutisk salt deraf.
9. Forbindelse ifølge krav 1, hvor forbindelsen er: (Ac-A6c7, Gln43)hGIP(7-43)-OH (SEQ ID NR: 29); eller et farmaceutisk acceptabelt salt deraf.
10. Forbindelse ifølge et hvilket som helst af kravene 1-9, yderligere omfattende en kovalent bundet PEG-enhed eller et farmaceutisk acceptabelt salt deraf, hvor PEG-enheden er udvalgt fra gruppen bestående af 5K PEG, 10K PEG, 20K PEG, 30K PEG, 40K PEG, 50K PEG og 60K PEG, til dannelse af Cys(succinimid-N-5K PEG), Cys(succinimid-N-10K PEG), Cys(succinimid-N-20K PEG), Cys(succinimid-N-30K PEG), Cys(succinimid-N-40K PEG), Cys(succinimid-N-50K PEG), Cys(succinimid-N-60K PEG) eller et farmaceutisk acceptabelt salt deraf.
11. Farmaceutisk sammensætning omfattende en virksom mængde af en forbindelse ifølge et hvilket som helst af kravene 1-10.
12. Forbindelse ifølge et hvilket som helst af kravene 1-10 eller en farmaceutisk sammensætning ifølge krav 11 til anvendelse i behandling af tilstande eller sygdomme medieret af GIP-receptorbinding i et individ, hvor behandlingen omfatter indgivelse af forbindelsen eller sammensætningen til individet i en terapeutisk virksom mængde, og hvor tilstanden eller sygdommen er udvalgt fra gruppen bestående af type 1 diabetes, type 2 diabetes, obesitet, insulinresistens, glucoseintolerance, fedtlever, glucagonomer, sekretoriske lidelser i luftvejene, stofskiftesygdomme, arthritis, osteoporose, sygdom i centralnervesystemet, restenose, neurodegenerativ sygdom, nyresvigt, kongestiv hjerteinsufficiens, nefrotisk syndrom, cirrose, lungeødem og hypertension.
13. Forbindelse eller sammensætning til anvendelse ifølge krav 12, hvor tilstanden eller sygdommen er type 2 diabetes.
14. Forbindelse ifølge et hvilket som helst af kravene 1-10 eller en farmaceutisk sammensætning ifølge krav 11 til anvendelse i behandling af diabetesrelaterede sygdomme i et individ, hvor behandlingen omfatter indgivelse af forbindelsen eller sammensætningen til individet i en terapeutisk virksom mængde, og hvor den diabetesrelaterede sygdom er udvalgt fra gruppen bestående af hyperglykæmi, hyperinsulinæmi, forringet glucose-tolerance, nedsat fastende glucose, dyslipidæmi, hypertriglyceridæmi og insulinresistens.
DK09805288T 2008-08-07 2009-08-07 Trunkerede analoger af glucoseafhængigt insulinotropt polypeptid DK2320923T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18819208P 2008-08-07 2008-08-07
US20062808P 2008-12-02 2008-12-02
PCT/US2009/004543 WO2010016935A2 (en) 2008-08-07 2009-08-07 Truncated analogues of glucose-dependent insulinotropic polypeptide

Publications (1)

Publication Number Publication Date
DK2320923T3 true DK2320923T3 (da) 2015-03-02

Family

ID=41664127

Family Applications (1)

Application Number Title Priority Date Filing Date
DK09805288T DK2320923T3 (da) 2008-08-07 2009-08-07 Trunkerede analoger af glucoseafhængigt insulinotropt polypeptid

Country Status (16)

Country Link
US (1) US8450266B2 (da)
EP (2) EP2915538A3 (da)
JP (2) JP2011530506A (da)
KR (2) KR101419332B1 (da)
CN (2) CN102170896A (da)
AU (1) AU2009280012B2 (da)
BR (1) BRPI0917001A2 (da)
CA (1) CA2733005C (da)
DK (1) DK2320923T3 (da)
EA (1) EA020018B1 (da)
ES (1) ES2528599T3 (da)
HK (2) HK1209344A1 (da)
MX (1) MX2011001028A (da)
PL (1) PL2320923T3 (da)
PT (1) PT2320923E (da)
WO (1) WO2010016935A2 (da)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110043688A (ko) 2008-08-07 2011-04-27 입센 파마 에스.에이.에스 포도당 의존적인 인슐린 분비 자극성 폴리펩타이드 유사체
WO2010016940A2 (en) 2008-08-07 2010-02-11 Ipsen Pharma S.A.S. Analogues of glucose-dependent insulinotropic polypeptide
DK2320923T3 (da) 2008-08-07 2015-03-02 Ipsen Pharma Sas Trunkerede analoger af glucoseafhængigt insulinotropt polypeptid
JP2013501766A (ja) 2009-08-10 2013-01-17 ユーシーエル ビジネス パブリック リミテッド カンパニー 固体基材の官能化
DE102010015123A1 (de) 2010-04-16 2011-10-20 Sanofi-Aventis Deutschland Gmbh Benzylamidische Diphenylazetidinone, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
US9023986B2 (en) 2010-10-25 2015-05-05 Hoffmann-La Roche Inc. Glucose-dependent insulinotropic peptide analogs
CN103764673A (zh) 2011-06-10 2014-04-30 北京韩美药品有限公司 葡萄糖依赖性促胰岛素多肽类似物、其药物组合物及应用
US20140377171A1 (en) * 2011-06-10 2014-12-25 Jean Claude Reubi Imaging and Treatment of Neuroendocrine Tumors with Glucose - Dependent Insulinotropic Polypeptide or Analogues or Antagonists Thereof
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
PL3189072T3 (pl) 2014-09-05 2019-04-30 Univ Copenhagen Analogi peptydowe gip
CN109715662B (zh) 2015-12-23 2023-07-21 美国安进公司 使用gipr结合蛋白与glp-1激动剂的组合来治疗或改善代谢病症的方法
JOP20190177A1 (ar) 2017-01-17 2019-07-16 Amgen Inc طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr)
JOP20180028A1 (ar) 2017-03-31 2019-01-30 Takeda Pharmaceuticals Co مركب ببتيد
WO2018220123A1 (en) 2017-05-31 2018-12-06 University Of Copenhagen Long-acting gip peptide analogues
EP3788063B1 (en) 2018-05-04 2023-08-09 Novo Nordisk A/S Gip derivatives and uses thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5672659A (en) 1993-01-06 1997-09-30 Kinerton Limited Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
NZ250844A (en) * 1993-04-07 1996-03-26 Pfizer Treatment of non-insulin dependant diabetes with peptides; composition
US5595760A (en) 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions
US5665702A (en) 1995-06-06 1997-09-09 Biomeasure Incorporated Ionic molecular conjugates of N-acylated derivatives of poly(2-amino-2-deoxy-D-glucose) and polypeptides
US6905550B2 (en) 1996-05-06 2005-06-14 Princeton Trade & Technology, Inc. Method of removing organic materials using aqueous cleaning solutions
US5916883A (en) 1996-11-01 1999-06-29 Poly-Med, Inc. Acylated cyclodextrin derivatives
AU5518798A (en) 1996-12-03 1998-06-29 Trustees Of Boston University Specific antagonists for glucose-dependent insulinotropic polypeptide (gip)
US7091183B1 (en) * 1996-12-03 2006-08-15 Boston Medical Center Corporation Specific antagonists for glucose-dependent insulinotropic polypeptide (GIP)
EP1053020B1 (en) 1998-01-29 2004-03-31 Poly-Med Inc. Absorbable microparticles
WO2000004916A1 (en) 1998-07-23 2000-02-03 Societe De Conseils De Recherches Et D'applications Scientifiques Sas Encapsulation of water soluble peptides
CA2353574C (en) 1998-12-07 2012-05-08 Zheng Xin Dong Analogues of glp-1
GB0404124D0 (en) 2004-02-25 2004-03-31 Univ Ulster Antagonists of GIP
DE60012721T4 (de) 1999-03-29 2010-09-09 Uutech Ltd., Coleraine Analoge des magensaft inhibierenden peptides und ihre verwendung für die behandlung von diabetes
US20050272652A1 (en) * 1999-03-29 2005-12-08 Gault Victor A Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
US20040048248A1 (en) * 1999-10-05 2004-03-11 Prayaga Sudhirdas K. Endozepine-like polypeptides and polynucleotides encoding same
WO2002082047A2 (en) * 2001-04-06 2002-10-17 California Institute Of Technology High throughput screening of crystallization of materials
TWI284539B (en) * 2001-07-30 2007-08-01 Epix Pharm Inc A method for making a magnetic resonance (MR) imaging agent, a MR imaging contrast agent, a method for altering stability of a peptide and a modified peptide
IL160359A0 (en) * 2001-08-31 2004-07-25 Avidex Ltd Soluble t cell receptor
US20030232761A1 (en) 2002-03-28 2003-12-18 Hinke Simon A. Novel analogues of glucose-dependent insulinotropic polypeptide
WO2003105760A2 (en) 2002-06-15 2003-12-24 Enteromed, Inc. Prevention and treatment of nonalcoholic fatty liver disease (nafld) by antagonism of the receptor to glucose-dependent insulinotropic polypeptide (gip)
ATE399185T1 (de) * 2002-12-31 2008-07-15 Nektar Therapeutics Al Corp Maleinsäureamid polymerderivate und ihre biokonjugate
US7259234B2 (en) * 2003-05-15 2007-08-21 Trustees Of Tufts College Stable analogs of peptide and polypeptide therapeutics
KR20070115947A (ko) * 2005-02-11 2007-12-06 아밀린 파마슈티칼스, 인크. 선택가능한 특성들을 가지는 ｇｉｐ 유사체 및 하이브리드폴리펩타이드
JPWO2007049695A1 (ja) * 2005-10-26 2009-04-30 中外製薬株式会社 凝集性ｇｌｐ−１アナログおよび徐放性医薬組成物
CA2660835A1 (en) 2006-08-17 2008-02-21 Amylin Pharmaceuticals, Inc. Dpp-iv resistant gip hybrid polypeptides with selectable propperties
DK2320923T3 (da) 2008-08-07 2015-03-02 Ipsen Pharma Sas Trunkerede analoger af glucoseafhængigt insulinotropt polypeptid

Also Published As

Publication number Publication date
JP2014051505A (ja) 2014-03-20
MX2011001028A (es) 2011-04-26
HK1154787A1 (en) 2012-05-04
KR20110043687A (ko) 2011-04-27
EA201170302A1 (ru) 2011-10-31
AU2009280012B2 (en) 2012-12-06
EP2320923A4 (en) 2012-07-18
CN104031140B (zh) 2017-04-12
CA2733005A1 (en) 2010-02-11
PL2320923T3 (pl) 2015-06-30
JP2011530506A (ja) 2011-12-22
BRPI0917001A2 (pt) 2016-02-16
EP2320923A2 (en) 2011-05-18
ES2528599T3 (es) 2015-02-10
HK1209344A1 (en) 2016-04-01
US20110136724A1 (en) 2011-06-09
CN102170896A (zh) 2011-08-31
WO2010016935A2 (en) 2010-02-11
US8450266B2 (en) 2013-05-28
CA2733005C (en) 2016-09-27
KR101419332B1 (ko) 2014-07-15
EP2320923B1 (en) 2014-12-24
EP2915538A3 (en) 2015-10-14
JP5864506B2 (ja) 2016-02-17
CN104031140A (zh) 2014-09-10
KR20130093693A (ko) 2013-08-22
WO2010016935A3 (en) 2010-04-08
PT2320923E (pt) 2015-02-24
EP2915538A2 (en) 2015-09-09
EA020018B1 (ru) 2014-08-29
AU2009280012A1 (en) 2010-02-11

Similar Documents

Publication Publication Date Title
DK2320923T3 (da) Trunkerede analoger af glucoseafhængigt insulinotropt polypeptid
CA2732949C (en) Analogues of glucose-dependent insulinotropic polypeptide
EP2323678B1 (en) Glucose-dependent insulinotropic polypeptide analogues
CA2733006A1 (en) Analogues of glucose-dependent insulinotropic polypeptide (gip) modified at n-terminal